The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Jan. 24, 12:58 PM

Slide #14. BiondVax Pharmaceuticals Ltd. Secondary Offering

Company: BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)
Date announced: 12/23/2021
Shares Offered: 3,813,560
Date of Pricing: 12/27/2021
Price Per Share: $2.36
Secondary Offering Details: BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it intends to offer its American Depositary Shares ("ADSs") in an underwritten public offering. -updated 12/27- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the pricing of an underwritten public offering of 3,813,560 American Depositary Shares ("ADSs") at a public offering price of $2.36 per ADS for gross proceeds to the Company of approximately $9.0 million, before deducting underwriting discounts and other offering expenses. Each ADS represents 40 ordinary shares of BiondVax. The offering is expected to close on or about December 29, 2021, subject to customary closing conditions. In connection with the offering, the Company has also granted the underwriters a 45-day option to purchase additional ADSs offered to the public at the public offering price, less underwriting discount, for covering over-allotments, if any. If the over-allotment option is exercised in full it would increase the total gross proceeds of the offering to approximately $9.8 million.

BiondVax Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and related illnesses. Co. has developed M-001, a flu vaccine candidate that was designed to provide multi-strain and multi-season protection against existing and future, seasonal and pandemic influenza. M-001 is intended to be intramuscularly injected into the body. Once administered, M-001 is designed to be recognized by the immune system, triggering both humoral and cellular immune reactions.
Open the BVXV Page at The Online Investor »

Company Name: 
BiondVax Pharmaceuticals Ltd
Website: 
www.biondvax.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BVXV: 
1
Total Market Value Held by ETFs: 
$120466
Total Market Capitalization: 
$18.00M
% of Market Cap. Held by ETFs: 
0.67%
 

Open the BVXV Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree BVXV Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.